{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:15:39Z","timestamp":1790846139493,"version":"4.1.0"},"reference-count":73,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4701\u2010B20, F4702\u2010B20, F4704\u2010B20, F4707\u2010B20, F6105\u2010B20"],"award-info":[{"award-number":["F4701\u2010B20, F4702\u2010B20, F4704\u2010B20, F4707\u2010B20, F6105\u2010B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"publisher","award":["14835"],"award-info":[{"award-number":["14835"]}],"id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Janus kinase 2 (JAK2) and signal transducer and activator of transcription-5 (STAT5) play a key role in the pathogenesis of myeloproliferative neoplasms (MPN). In most patients, JAK2 V617F or CALR mutations are found and lead to activation of various downstream signaling cascades and molecules, including STAT5. We examined the presence and distribution of phosphorylated (p) STAT5 in neoplastic cells in patients with MPN, including polycythemia vera (PV, n = 10), essential thrombocythemia (ET, n = 15) and primary myelofibrosis (PMF, n = 9), and in the JAK2 V617F-positive cell lines HEL and SET-2. As assessed by immunohistochemistry, MPN cells displayed pSTAT5 in all patients examined. Phosphorylated STAT5 was also detected in putative CD34+\/CD38\u2212 MPN stem cells (MPN-SC) by flow cytometry. Immunostaining experiments and Western blotting demonstrated pSTAT5 expression in both the cytoplasmic and nuclear compartment of MPN cells. Confirming previous studies, we also found that JAK2-targeting drugs counteract the expression of pSTAT5 and growth in HEL and SET-2 cells. Growth-inhibition of MPN cells was also induced by the STAT5-targeting drugs piceatannol, pimozide, AC-3-019 and AC-4-130. Together, we show that CD34+\/CD38\u2212 MPN-SC express pSTAT5 and that pSTAT5 is expressed in the nuclear and cytoplasmic compartment of MPN cells. Whether direct targeting of pSTAT5 in MPN-SC is efficacious in MPN patients remains unknown.<\/jats:p>","DOI":"10.3390\/cancers12041021","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T04:15:13Z","timestamp":1587528913000},"page":"1021","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["STAT5 is Expressed in CD34+\/CD38\u2212 Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-4204","authenticated-orcid":false,"given":"Emir","family":"Hadzijusufovic","sequence":"first","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department\/Hospital for Companion Animals and Horses, University Hospital for Small Animals, Internal Medicine Small Animals, University of Veterinary Medicine Vienna, 1210 Vienna, Austria"},{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Keller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berger","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-4117","authenticated-orcid":false,"given":"Georg","family":"Greiner","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6108-5245","authenticated-orcid":false,"given":"Bettina","family":"Wingelhofer","sequence":"additional","affiliation":[{"name":"Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Witzeneder","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-4224","authenticated-orcid":false,"given":"Daniel","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Pecnard","sequence":"additional","affiliation":[{"name":"INSERM, ERI-12, Facult\u00e9 de Pharmacie, Universit\u00e9 de Picardie Jules Verne, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Nivarthi","sequence":"additional","affiliation":[{"name":"Research Center for Molecular Medicine (CeMM), 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian K. M.","family":"Schur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00fcksel","family":"Filik","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kornauth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-7786","authenticated-orcid":false,"given":"Heidi A.","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-078X","authenticated-orcid":false,"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tin","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvin D.","family":"de Araujo","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Gunning","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-4380","authenticated-orcid":false,"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6047-1718","authenticated-orcid":false,"given":"Fabrice","family":"Gouilleux","sequence":"additional","affiliation":[{"name":"INSERM, ERI-12, Facult\u00e9 de Pharmacie, Universit\u00e9 de Picardie Jules Verne, 80000 Amiens, France"},{"name":"CNRS UMR 6239, GICC, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Fran\u00e7ois Rabelais, 37020 Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kralovics","sequence":"additional","affiliation":[{"name":"Research Center for Molecular Medicine (CeMM), 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moriggl","sequence":"additional","affiliation":[{"name":"Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5095","authenticated-orcid":false,"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Department\/Hospital for Companion Animals and Horses, University Hospital for Small Animals, Internal Medicine Small Animals, University of Veterinary Medicine Vienna, 1210 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.22210","article-title":"Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbmt.2015.09.005","article-title":"Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups","volume":"21","author":"Deeg","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/156800911793743592","article-title":"Current treatment concepts of Philadelphia-negative MPN","volume":"11","author":"Wolf","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11899-011-0109-7","article-title":"Management of myeloproliferative neoplasms: From academic guidelines to clinical practice","volume":"7","author":"Barosi","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/14737140.9.1.37","article-title":"Anagrelide: 20 years later","volume":"9","author":"Emadi","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2016","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1074\/jbc.M109.040733","article-title":"STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant","volume":"285","author":"Tago","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.humpath.2007.10.034","article-title":"Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F","volume":"39","author":"Gibson","year":"2008","journal-title":"Hum. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2017.01.050","article-title":"JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms","volume":"451","author":"Harrison","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.clml.2014.06.014","article-title":"Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy","volume":"14","author":"Pasquier","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: Subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2006-01-029918","article-title":"Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias","volume":"109","author":"Harir","year":"2007","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/cancers7010503","article-title":"Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells","volume":"7","author":"Weber","year":"2015","journal-title":"Cancers"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2016.06.009","article-title":"Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms","volume":"48","author":"Angona","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis","volume":"110","author":"Chaligne","year":"2007","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4161\/jkst.22071","article-title":"The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective","volume":"1","author":"Staerk","year":"2012","journal-title":"JAK-STAT"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/leu.2008.226","article-title":"SOCS2: Inhibitor of JAK2V617F-mediated signal transduction","volume":"22","author":"Quentmeier","year":"2008","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.V93.7.2369","article-title":"Constitutive activation of the JAK2\/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines","volume":"93","author":"Liu","year":"1999","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2010.036350","article-title":"Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors","volume":"96","author":"Hornakova","year":"2011","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"96710","DOI":"10.18632\/oncotarget.18073","article-title":"Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A\/CIP2A axis","volume":"8","author":"Bartalucci","year":"2017","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/leu.2017.338","article-title":"Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells","volume":"32","author":"Peter","year":"2018","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","article-title":"Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors","volume":"13","author":"Geron","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2013-05-505735","article-title":"Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells","volume":"123","author":"Cook","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/jm1011319","article-title":"Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak\/Stat pathway","volume":"54","author":"Ioannidis","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12661","DOI":"10.1074\/jbc.275.17.12661","article-title":"Distinct mechanisms of STAT phosphorylation via the interferon-alpha\/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol","volume":"275","author":"Su","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cmdc.201700234","article-title":"Effects of Pimozide Derivatives on pSTAT5 in K562 Cells","volume":"12","author":"Rondanin","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/ml500165r","article-title":"Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein","volume":"5","author":"Cumaraswamy","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","article-title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.17219\/acem\/32934","article-title":"Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K\/mTOR Inhibitors in JAK2-Positive Human Cell Lines","volume":"24","author":"Szymanska","year":"2015","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bogani, C., Bartalucci, N., Martinelli, S., Tozzi, L., Guglielmelli, P., Bosi, A., Vannucchi, A.M., and Associazione Italiana per la Ricerca sul Cancro, A.G.I.M.M. (2013). mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054826"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2011.338","article-title":"Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells","volume":"26","author":"Nelson","year":"2012","journal-title":"Leukemia"},{"key":"ref_54","unstructured":"(Personal observation, 2018). Emir Hadzijusufovic (Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria), Personal observation."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/leu.2017.4","article-title":"O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies","volume":"31","author":"Freund","year":"2017","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Prestipino, A., Emhardt, A.J., Aumann, K., O\u2019Sullivan, D., Gorantla, S.P., Duquesne, S., Melchinger, W., Braun, L., Vuckovic, S., and Boerries, M. (2018). Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med., 10.","DOI":"10.1126\/scitranslmed.aam7729"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2017.36","article-title":"Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics","volume":"31","author":"Reckel","year":"2017","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1038\/onc.2012.369","article-title":"Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells","volume":"32","author":"Chatain","year":"2013","journal-title":"Oncogene"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","article-title":"Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: Possible new targets of therapy","volume":"99","author":"Bibi","year":"2014","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2007-05-090969","article-title":"Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD","volume":"110","author":"Bunting","year":"2007","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-015-0113-9","article-title":"Cancer stem cells in basic science and in translational oncology: Can we translate into clinical application?","volume":"8","author":"Schulenburg","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/0008-5472.CAN-14-3225","article-title":"Cancer stem cells: Targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance","volume":"75","author":"Kibria","year":"2015","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","article-title":"Activation of JAK\/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo","volume":"25","author":"Woods","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Vainchenker, W., Constantinescu, S.N., and Plo, I. (2016). Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Research, 5.","DOI":"10.12688\/f1000research.8081.1"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/stem.2888","article-title":"JAK2V617F Megakaryocytes Promote Hematopoietic Stem\/Progenitor Cell Expansion in Mice Through Thrombopoietin\/MPL Signaling","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2007-01-069237","article-title":"Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Abba, C., Campanelli, R., Catarsi, P., Villani, L., Abbonante, V., Sesta, M.A., Barosi, G., Rosti, V., and Massa, M. (2019). Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220189"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Nivarthi","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2015.138","article-title":"Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia","volume":"29","author":"Wedeh","year":"2015","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/1021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:09:12Z","timestamp":1760364552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/1021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["cancers12041021"],"URL":"https:\/\/doi.org\/10.3390\/cancers12041021","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]}}}